On November 13, 2023, Gelonghui reported that sh pharma (601607.SH) announced that on November 13, 2024, the company received a "Simplified Report on Equity Change" from its shareholder new china life insurance co., ltd. (referred to as "new china life insurance" or "information disclosure obligor"). On November 12, 2024, new china life insurance increased its shareholding in sh pharma by acquiring 9,999,836 unrestricted circulating A shares and 1,500,000 H shares through a concentrated bidding trading method in the secondary market. The funds for this increase came from its own funds.
After this change in equity, new china life insurance holds 148,951,274 A shares of sh pharma, accounting for approximately 4.02% of the company's total share capital. It holds 37,895,900 H shares of sh pharma, accounting for approximately 1.02% of the company’s total share capital. New china life insurance asset management co., ltd. (referred to as "new china life asset management", as of the announcement date, new china life insurance holds 99.4% of new china life asset management, which constitutes a concerted party of new china life insurance) issued composite asset management products that hold 222,300 A shares of sh pharma, accounting for approximately 0.01% of the company's total share capital. The information disclosure obligor and its concerted parties together hold 149,173,574 A shares and 37,895,900 H shares of sh pharma, accounting for approximately 5.05% of the company's total share capital.
This equity change is because the proportion of issued shares held by new china life insurance and its concerted party new china life asset management reached over 5%, which does not trigger a mandatory takeover offer.
